These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 26699825)

  • 41. Summaries for patients. Benefits and risks of continuing aspirin in patients with peptic ulcer bleeding.
    Ann Intern Med; 2010 Jan; 152(1):I-20. PubMed ID: 19949137
    [No Abstract]   [Full Text] [Related]  

  • 42. Intravenous proton-pump inhibitors versus H2-antagonists for treatment of GI bleeding.
    Huggins RM; Scates AC; Latour JK
    Ann Pharmacother; 2003 Mar; 37(3):433-7. PubMed ID: 12639176
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Increased use of acid-suppressing drugs before the occurrence of ischemic events: a potential source of confounding in recent observational studies.
    Blackburn DF; Lamb DA; Mcleod MM; Eurich DT
    Pharmacotherapy; 2010 Oct; 30(10):985-93. PubMed ID: 20874035
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Bleeding in the upper part of the gastrointestinal tract due to stress ulcers.
    Carlson RW; Baker L; Andhavarapu S
    Am J Crit Care; 2008 Mar; 17(2):148-9. PubMed ID: 18310652
    [No Abstract]   [Full Text] [Related]  

  • 45. [Investigation into the effect of gastric secretion inhibitor for the prevention of upper gastrointestinal lesions associated with low-dose aspirin].
    Nakamura H; Yokoyama H; Yaguchi T; Suzuki Y; Tokuoka K; Watanabe M; Kitagawa Y; Yamada Y
    Yakugaku Zasshi; 2011 Mar; 131(3):445-52. PubMed ID: 21372542
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prevention of Dabigatran-Related Gastrointestinal Bleeding With Gastroprotective Agents: A Population-Based Study.
    Chan EW; Lau WC; Leung WK; Mok MT; He Y; Tong TS; Wong IC
    Gastroenterology; 2015 Sep; 149(3):586-95.e3. PubMed ID: 25960019
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Risk factors of upper gastrointestinal complications in outpatients on antiplatelet therapy: description and management].
    Ducrocq G; Bigard MA; Marouene S; Delaage PH; Fabry C; Barthelemy P; Steg PG;
    Ann Cardiol Angeiol (Paris); 2012 Aug; 61(4):245-51. PubMed ID: 22579299
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Aspirin and proton pump inhibitor combination therapy for prevention of cardiovascular disease and Barrett's esophagus.
    Peura DA; Wilcox CM
    Postgrad Med; 2014 Jan; 126(1):87-96. PubMed ID: 24393755
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clopidogrel. Patients with peptic ulcers.
    Beales IL
    BMJ; 2009 May; 338():b1932. PubMed ID: 19457957
    [No Abstract]   [Full Text] [Related]  

  • 50. Pharmacologic therapy for nonvariceal upper gastrointestinal bleeding.
    Wu JC; Sung JJ
    Gastrointest Endosc Clin N Am; 2011 Oct; 21(4):671-9. PubMed ID: 21944417
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Analysis of gastrointestinal prophylaxis in patients receiving dual antiplatelet therapy with aspirin and clopidogrel.
    Morneau KM; Reaves AB; Martin JB; Oliphant CS
    J Manag Care Pharm; 2014 Feb; 20(2):187-93. PubMed ID: 24456320
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparison of adjuvant therapies by an H2-receptor antagonist and a proton pump inhibitor after endoscopic treatment in hemostatic management of bleeding gastroduodenal ulcers.
    Sakurada T; Kawashima J; Ariyama S; Kani K; Takabayashi H; Ohno S; Kato S; Yakabi K
    Dig Endosc; 2012 Mar; 24(2):93-9. PubMed ID: 22348833
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Effect of H2-receptor antagonist and proton pomp inhibitor on the treatment of acid-related disease].
    Kawai T; Yagi K; Moriyasu F
    Nihon Rinsho; 2015 Jul; 73(7):1159-62. PubMed ID: 26165073
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Commentary: improving the use of gastroprotective agents among high-risk NSAID users.
    Howden CW
    Aliment Pharmacol Ther; 2013 May; 37(10):1019. PubMed ID: 23590536
    [No Abstract]   [Full Text] [Related]  

  • 55. Underutilization of gastroprotection for at-risk patients undergoing percutaneous coronary intervention: Spain compared with the United States.
    Casado-Arroyo R; Scheiman JM; Polo-Tomas M; Saini SD; Del Rio A; Guastello E; Lanas A
    Aliment Pharmacol Ther; 2010 Sep; 32(5):689-95. PubMed ID: 20626380
    [TBL] [Abstract][Full Text] [Related]  

  • 56. New look at antiplatelet agent-related peptic ulcer: an update of prevention and treatment.
    Hsu PI
    J Gastroenterol Hepatol; 2012 Apr; 27(4):654-61. PubMed ID: 22283743
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Unintended consequences of therapy in the intensive care unit.
    Kim R; Goss CH
    JAMA Intern Med; 2014 Apr; 174(4):574-6. PubMed ID: 24534847
    [No Abstract]   [Full Text] [Related]  

  • 58. Combining aspirin and proton pump inhibitors: for whom the warning bell tolls?
    Würtz M; Grove EL
    Expert Opin Drug Metab Toxicol; 2012 Sep; 8(9):1051-5. PubMed ID: 22834712
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [The new algorithm of diagnostics, prevention and treatment of acute erosive and ulcerative lesions of the gastrointestinal tract].
    Dzhitava IG; Smirnova GO; Martirosov AV
    Eksp Klin Gastroenterol; 2011; (5):63-8. PubMed ID: 21916237
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Antiplatelet and anticoagulant therapy in patients with gastrointestinal bleeding: an 86-year-old woman with peptic ulcer disease.
    Almadi MA; Barkun A; Brophy J
    JAMA; 2011 Dec; 306(21):2367-74. PubMed ID: 22045703
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.